儿童克罗恩病患者生物制剂停用特征分析
这项多中心研究分析了2010至2020年美国7家中心823例儿童克罗恩病患者,86%启动生物制剂,29%停用首种生物制剂,中位停药时间793天。 proactive TDM和联用免疫调节剂与生物制剂停用风险降低相关。
要点
- 86%的儿童克罗恩病患者启动生物制剂,29%停用首种生物制剂,中位停药时间793天。
- 停用原因包括无效(34%)、抗药抗体(8%)、不良事件(8%)和不依从(12%)。
- 主动TDM和联用免疫调节剂分别与生物制剂停用风险降低60%和32%相关。
核心结论
- 多数儿童克罗恩病患者接受生物制剂治疗,25%至37%停用生物制剂,导致每12例中有1例在儿科诊疗期间使用超过2种生物制剂。
- 半数患者未尝试高剂量治疗即停用生物制剂,14%未进行任何评估即停用。
- 联用免疫调节剂和主动TDM可降低生物制剂停用风险。
研究设计与样本
- 研究纳入2010至2020年美国7家中心的儿童克罗恩病患者,前瞻性ImproveCareNow登记数据辅以病历摘录。
- 共纳入823例患者,中位年龄13.0岁,40%为女性。
- 生物制剂包括单克隆抗体和小分子药物。
主要发现
- 86%的患者启动生物制剂,其中78%使用英夫利西单抗,21%使用阿达木单抗,不足1%使用其他生物制剂。
- 26%的患者联用免疫调节剂至少12个月。
- 85%的患者进行TDM,其中47%为诱导期,69%为主动监测,24%为被动监测。
- 29%的患者停用首种生物制剂,中位停药时间793天,原因包括无效(34%)、抗药抗体(8%)、不良事件(8%)和不依从(12%)。
- 因无效停药者中86%进行了停药前评估;因英夫利西单抗或阿达木单抗无效且进行TDM者中,62%药物谷浓度低于10 μg/mL。
关键数值与推荐
- 主动TDM与生物制剂停用风险降低60%相关。
- 联用免疫调节剂与生物制剂停用风险降低32%相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Biologic therapies may effectively treat Crohn's disease (CD), and pediatric patients who discontinue multiple biologics risk exhausting treatment options. The frequency and context of biologic discontinuation have not been well-characterized. We aimed to determine patterns of biologic use, discontinuation, and evaluation in pediatric patients with CD. METHODS: Pediatric patients with CD at 7 U.S. centers (2010-2020) were identified. Prospective ImproveCareNow registry data were supplemented with medical record abstraction. Biologics included monoclonal antibody and small molecule medications. Therapeutic drug monitoring (TDM) was considered induction if <14 weeks after biologic start, proactive if later during quiescent disease, and reactive during active disease. RESULTS: Of 823 patients included (median age, 13.0 years; 40% female), 86% started biologics (78% infliximab, 21% adalimumab, <1% others). Twenty-six percent used concomitant immunomodulators for ≥12 months. Most (85%) measured TDM including 47% induction, 69% proactive, and 24% reactive. Twenty-nine percent discontinued their first biologic after median 793 days because of inefficacy (34%), anti-drug antibodies (8%), adverse events (8%), or non-adherence (12%). If inefficacy, 86% underwent pre-discontinuation evaluation. If infliximab or adalimumab inefficacy and TDM was done, 62% had levels <10 μg/mL. Proactive TDM and concomitant immunomodulators were associated with 60% and 32% reduced biologic discontinuation. CONCLUSIONS: Most children with CD are treated with biologics; 25%-37% discontinue biologics, resulting in 1 in 12 using >2 biologics during pediatric care. Half of patients discontinued biologics without trial of high-dose therapy and 14% without any evaluation. Concomitant immunomodulator use and proactive TDM decreased risk of biologic discontinuation. Strategies are needed to preserve biologic efficacy and prevent biologic discontinuation.
引用
- Ali S, Pasternak B, Moses J, et al. Characterization of Biologic Discontinuation Among Pediatric Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2024. PMID: 38723980. doi:10.1016/j.cgh.2024.03.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。